LXRα improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes by unknown
ARTICLE
LXRα improves myocardial glucose tolerance and reduces
cardiac hypertrophy in a mouse model of obesity-induced
type 2 diabetes
Megan V. Cannon1 & Herman H. W. Silljé1 & Jürgen W. A. Sijbesma2 &
Mohsin A. F. Khan1 & Knut R. Steffensen3 & Wiek H. van Gilst1 & Rudolf A. de Boer1
Received: 15 July 2015 /Accepted: 5 November 2015 /Published online: 18 December 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Aims/hypothesis Diabetic cardiomyopathy is a myocardial
disease triggered by impaired insulin signalling, increased
fatty acid uptake and diminished glucose utilisation. Liver X
receptors (LXRs) are key transcriptional regulators of meta-
bolic homeostasis. However, their effect in the diabetic heart is
largely unknown.
Methods We cloned murine Lxrα (also known as Nr1h3) be-
hind the α-myosin heavy chain (αMhc; also known asMyh6)
promoter to create transgenic (Lxrα-Tg) mice and transgene-
negative littermates (wild-type [WT]). A mouse model of type
2 diabetes was induced by a high-fat diet (HFD, 60% energy
from fat) over 16 weeks and compared with a low-fat diet
(10% energy from fat). A mouse model of type 1 diabetes
was induced via streptozotocin injection over 12 weeks.
Results HFD manifested comparable increases in body
weight, plasma triacylglycerol and insulin resistance per
OGTT in Lxrα-Tg andWTmice. HFD significantly increased
left ventricular weight by 21% in WT hearts, but only by 5%
in Lxrα-Tg. To elucidate metabolic effects in the heart,
microPET (positron emission tomography) imaging revealed
that cardiac glucose uptake was increased by 1.4-fold in WT
mice on an HFD, but further augmented by 1.7-fold in Lxrα-
Tg hearts, in part through 5′ adenosine monophosphate-
activated protein kinase (AMPK) phosphorylation and resto-
ration of glucose transporter 4 (GLUT4). By contrast,
streptozotocin-induced ablation of insulin signalling dimin-
ished cardiac glucose uptake levels and caused cardiac dys-
function, indicating that insulin may be important in LXRα-
mediated glucose uptake. Chromatin immunoprecipitation as-
says identified natriuretic peptides, atrial natriuretic peptide
(ANP) and B-type natriuretic peptide (BNP), as potential di-
rect targets of cardiac LXRα overexpression.
Conclusions/interpretation Cardiac-specific LXRα overex-
pression ameliorates the progression of HFD-induced left
ventricular hypertrophy in association with increased glucose
reliance and natriuretic peptide signalling during the early
phase of diabetic cardiomyopathy. These findings implicate
a potential protective role for LXR in targeting metabolic
disturbances underlying diabetes.
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Introduction
Metabolic abnormalities such as insulin resistance, disturbed
glucose homeostasis, dyslipidaemia and obesity collectively
predispose individuals toward the development of type 2
diabetes and are associated with an increased risk of cardio-
vascular disease and heart failure [1]. Moreover, obesity pro-
motes left ventricular (LV) hypertrophy independent of hyper-
tension [2], and LV hypertrophy is not uncommon in normo-
tensive individuals with diabetes [3]. The underlying patho-
genesis of myocardial disease induced by diabetes, referred to
as diabetic cardiomyopathy, is only partially understood.
However, aberrant myocardial metabolism is implicated in
the early manifestation of the disease, as increased circulating
fatty acids (FA) and impaired insulin signalling cause a shift in
substrate usage towards exclusively favouring FA over glu-
cose. The consequent lack of metabolic flexibility leads to
lipotoxicity, impaired calcium signalling and mitochondrial
dysfunction, which manifests as increased myocardial stiff-
ness, hypertrophy and diastolic dysfunction [4].
Liver X receptors α and β (LXRα and LXRβ) are sterol-
activated transcription factors belonging to the nuclear recep-
tor superfamily. LXRs activate target gene transcription
through heterodimerization with the retinoid X receptor
(RXR) and by interacting with an LXR response element
(LXRE). LXRs have emerged as central regulators of choles-
terol homeostasis and lipid and glucose metabolism, and have
established anti-inflammatory and immune functions. In
insulin-resistant diabetic rodents, synthetic LXR activation
has been shown to reduce hyperglycaemia [5, 6] and improve
peripheral insulin sensitivity [7, 8], effects that are mediated
across multi-organ systems including suppression of
gluconeogenic genes in the liver and improved peripheral glu-
cose disposal in adipose tissue [5, 7] and skeletal muscle [9].
LXRs also play an important role in the normal and diabetic
kidney through regulation of intracellular cholesterol and in-
flammation [10]. In the heart, activation of LXRs has been
shown to attenuate pathological cardiac hypertrophy
[11–13], ischaemia/reperfusion injury [14, 15], and very re-
cently, diabetic cardiomyopathy in a db/db mouse model of
type 2 diabetes [16].
We have previously shown that mice with selective over-
expression of LXRα in the heart (Lxrα-Tg) demonstrate in-
creased capacity for myocardial glucose uptake that protects
against cardiac dysfunction and adverse remodelling in the
adaptation to hypertrophic stress [17]. To date, the metabolic
effects of LXRs in the diabetic heart have not been described.
Here, we investigate the metabolic and functional conse-
quences of cardiac LXRα activation in response to a metabol-
ic challenge imposed by high-fat diet (HFD)-induced obesity
and insulin resistance.
Methods
A detailed description of methods is provided in the electronic
supplementary material (ESM Methods).
Generation of Lxrα-Tg mice Transgenic mice with cardiac-
specific LXRα overexpression were created by cloning a full-
length murine Lxrα (also known as Nr1h3) complementary
DNA (cDNA) construct downstream of the cardiac-specific
α-myosin heavy chain (αMhc; also known asMyh6) promot-
er, as previously described [17]. Mice were bred on a C57BL/
6 background and backcrossed for six generations.
Nontransgenic littermates (wild-type, WT) served as controls.
Experimental protocol Animal studies were performed in
accordance with the principles of laboratory animal care
(NIH publication no. 85-23, revised 1985) and with approval
by the Institutional Animal Care and Use Committee of the
University of Groningen, Groningen, the Netherlands. To in-
duce a model of type 2 diabetes, diet intervention commenced
in male mice of approximately 12 weeks of age; they received
either an HFD (60% energy from fat) or a nutrient-equivalent
low-fat control diet (LFD; 10% energy from fat) for 16 weeks.
To induce a model of type 1 diabetes over a 12-week period, a
low-dose streptozotocin (STZ) induction protocol was per-
formed (50 mg/kg STZ administered intraperitoneally for 5
consecutive days).
Cardiac function was assessed with echocardiography and
invasive haemodynamic monitoring, and myocardial glucose
uptake was determined using 2-deoxy-2-[18F]fluoro-D-glu-
cose ([18F]FDG) and microPET (positron emission tomogra-
phy) imaging, as previously described [17, 18]. AnOGTTwas
performed whereby mice were challenged with a glucose bo-
lus (2 g/kg) and blood glucose levels were measured across a
3 h time course. LV tissue samples were used to perform
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quantitative real-time PCR and immunoblotting, biochemical
assays and histological analysis, as described previously [17].
Chromatin immunoprecipitation assay Chromatin immu-
noprecipitation (ChIP) experiments were performed in both
isolated neonatal rat ventricular myocytes and in hearts from
Lxrα-Tg and WT mice using the Pierce Agarose ChIP Kit
(Thermo Scientific, Rockford, IL, USA).
Statistics Data are expressed as means±SEM. For group
comparisons, one-way ANOVA was performed followed by
Tukey’s post hoc analysis. When the data were not normally
distributed according to Shapiro–Wilk test for normality,
Kruskal–Wallis test followed by a Mann–Whitney U test for
individual comparison of means were performed. A value of
p<0.05 was considered statistically significant. Statistical
analyses were performed using IBM SPSS Statistics 22
(Chicago, IL, USA).
Results
HFD induces obesity and insulin resistance in mice Prior to
diet intervention, all Lxrα-Tg mice in the LFD and HFD
groups displayed comparable measures of body weight with
respect to WT mice (Fig. 1a). Obesity developed similarly
between Lxrα-Tg and WT mice on HFD as both groups
gained significant and proportional increases in body weight
in the first 8 weeks; by 16 weeks, mice attained approximately
50% of their original bodyweight (Table 1).Mice receiving an
HFD exhibited hypertriglyceridaemia and hyperinsulinaemia,
as both circulating triacylglycerol (Fig. 1b) and insulin levels
(Fig. 1c) were significantly elevated compared with respective
LFD controls. Mice on an HFD were normoglycaemic, yet
demonstrated glucose intolerance and insulin resistance per
OGTT (Fig. 1d, e). AUC (Fig. 1d) was calculated from re-
sponse to oral glucose challenge (Fig. 1e). In both HFD
groups, post-mortem analysis revealed significant increases
in liver weight of 46% and 50% for WT-HFD and
Lxrα-Tg -HFD, respectively (Table 1). These data suggest that
both Lxrα-Tg and WT mice incurred comparable systemic
effects from HFD intervention, resembling human insulin re-
sistance and impaired glucose tolerance/fasting glucose. The
HFD did not affect ventricular LXRα protein expression as
assessed by western blot (Fig. 1f).
Cardiac LXRα overexpression prevents development of
LV hypertrophy induced by HFD HFD feeding over
16 weeks caused a significant increase of 21% in LV weight
of WT mice, but only 5% in Lxrα-Tg mice (Fig. 2a). Expres-
sion of the adult cardiac gene, αMhc, was significantly down-
regulated in WT mice on an HFD (Fig. 2b), whereas the fetal
isoform, βMhc (also known as Myh7), was significantly
higher inWT than in Lxrα-Tg mice (Fig. 2c). Transcript levels
of skeletal muscle alpha-actin (Acta1) were increased similar-
ly in both HFD groups (Fig. 2d), whereas regulator of
Fig. 1 Lxrα-Tg andWTmice develop obesity and insulin resistancewith
high-fat feeding. (a, e) Circles, LFD; triangles, HFD; black symbols, WT;
white symbols, Lxrα-Tg . (b–d) White bars, WT; black bars, Lxrα-Tg .
(a) Body weight increased in mice after 16 weeks of an HFD (n=11–12/
group). Measurements of fasted plasma (b) triacylglycerol and (c) insulin
levels (n=8–12/group). (d, e) OGTTswere performed inmice at 14weeks
(n=9–10/group). (d) AUC was calculated from (e) serial glucose mea-
surements. All data are means±SEM. *p<0.05 vs respective LFD control
for both Lxrα-Tg and WT; **p<0.01, ***p<0.001 vs respective LFD
control; ††p<0.01 WT LFD vs WT HFD. (f) Western blot of LV LXRα
protein expression in mice subjected to LFD or HFD; glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) served as loading control
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calcineurin 1 (Rcan1) was significantly induced inWT but not
in Lxrα-Tg mice (Fig. 2e). Interestingly, natriuretic peptides,
atrial natriuretic peptide (Anp, also known as Nppa) and B-
type natriuretic peptide (Bnp, also known as Nppb) were up-
regulated in Lxrα-Tg hearts, irrespective of diet (Fig. 2f, g).
Potential growth pathways implicated in cardiac hypertro-
phy and diabetic cardiomyopathy were also studied. Phos-
phorylated AktSer473 protein levels were moderately upregu-
lated similarly between Lxrα-Tg andWTmice on HFD (ESM
Fig. 1a). In both HFD groups, downstream effects of Akt
signalling strongly phosphorylated and activated the ribosom-
al protein S6 kinase more than threefold, with moderate ef-
fects on P70S6 kinase signalling (ESM Fig. 1b, c). HFD in-
tervention did not result in upregulation of pathological extra-
cellular signal-regulated kinase (ERK) and phosphorylated
p44/42 mitogen-activated protein kinase (MAPK) pathways
(ESM Fig. 1d). These data suggest that phospho-AktSer473–S6
signalling mediates cardiac growth due to HFD in both
Table 1 Biometric, echocardio-
graphic and haemodynamic vari-
ables of Lxrα-Tg and WT mice
after 16 weeks of an LFD or HFD
Variable LFD HFD
WT Lxrα-Tg WT Lxrα-Tg
Post-mortem organ weight (n=11) (n=11) (n=12) (n=12)
Body weight (g) 34.8±1.3 35.0±0.9 50.9±0.8*** 53.4±0.7***
LV/body weight (mg/g) 3.5±0.1 3.2±0.2 2.8±0.1*** 2.2±0.2***,†††
LV/tibia (mg/mm) 6.9±0.1 6.3±0.2 8.3±0.2*** 6.6±0.5*,†††
Kidney/tibia (mg/mm) 23.5±0.7 24.6±0.8 25.1±0.6 26.5±0.6
Liver/tibia (mg/mm) 92.7±5.8 89.8±6.4 172.8±9.1*** 182.6±7.0***
Echocardiography (n=11) (n=10) (n=12) (n=12)
Heart rate (bpm) 436±10 436±12 418±9 456±13
LVCO/BW (ml min−1 g−1) 0.81±0.04 0.72±0.09 0.67±0.04 0.70±0.04
Stroke volume (μl) 66.3±2.6 63.8±2.7 82.9±5.0* 82.3±4.4**
Fractional shortening (%) 40.9±1.5 41.9±1.1 35.2±2.2 36.4±1.3
LV posterior wall, diastole (mm) 0.78±0.03 0.80±0.04 1.10±0.19** 0.88±0.02***
LV posterior wall, systole (mm) 1.43±0.05 1.51±0.09 1.45±0.06 1.40±0.05
Interventricular septum, diastole
(mm)
0.78±0.02 0.72±0.01 0.98±0.05** 0.92±0.04***,†††
Interventricular septum, systole
(mm)
1.48±0.04 1.41±0.05 1.60±0.07 1.56±0.06
LV internal diameter, diastole
(mm)
4.00±0.10 3.73±0.11 4.02±0.13 4.26±0.07**
LV internal diameter, systole (mm) 2.37±0.10 2.17±0.09 2.60±0.13 2.63±0.12*
E velocity (m/s) 0.76±0.02 0.71±0.02 0.71±0.03 0.77±0.07
A velocity (m/s) 0.54±0.02 0.51±0.03 0.47±0.03 0.52±0.06
E/A ratio 1.41±0.03 1.43±0.06 1.59±0.11 1.57±0.10
Deceleration time (ms) 44.6±2.8 36.7±2.5 43.8±4.1 37.4±2.4
Haemodynamics (n=11) (n=11) (n=12) (n=12)
Aortic pressures
Systolic (mmHg) 101.1±2.2 92.1±2.7 105.8±2.6 105.8±2.3**
Diastolic (mmHg) 66.5±1.9 63.8±1.8 69.9±2.0 70.4±1.4
Mean arterial pressure
(mmHg)




99.8±2.0 91.5±2.7 110.7±4.0 103.2±2.6*
LVend-diastolic pressure
(mmHg)
7.6±2.2 7.2±1.4 10.4±1.2 13.5±2.0
dP/dtmax (mmHg) 8,360±363 8,420±305 8,389±375 8,263±293
dP/dtmin (mmHg) −7,785±365 −7,433±265 −8,135±348 −7,197±340
Data are expressed as means±SEM
*p<0.05, **p<0.01, ***p<0.001, HFD versus corresponding LFD group; ††† p<0.001 WT vs Lxrα-Tg mice
bpm, beats per minute; LVCO, left ventricular cardiac output; BW, body weight
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Lxrα-Tg and WT mice, but is antagonised by the anti-
hypertrophic effects of enhanced natriuretic peptides in hearts
overexpressing cardiac LXRα.
HFD causes mild hypertension and borderline diastolic
and systolic dysfunction Echocardiographic and invasive
haemodynamic variables of cardiac function are presented in
Table 1. Mean arterial pressure and intracardiac pressures did
not differ significantly between Lxrα-Tg andWTmice. Blood
pressure levels tended to be lower in Lxrα-Tg mice and in-
creased with HFD, but not in WT mice. Mice on an HFD did
not display signs of diastolic dysfunction, as mitral filling
velocities and deceleration time were unaltered, as well as
end-diastolic LV pressure and contractility. These data indi-
cate that the associated HFD-induced LV hypertrophy
represents early structural remodelling since functional conse-
quences are absent at this time point.
Lxrα-Tg mice demonstrate increased cardiac glucose
uptake despite systemic insulin resistance We have previ-
ously demonstrated enhanced myocardial glucose uptake in
Lxrα-Tg mice and in response to chronic pressure overload-
induced hypertrophy [17]. In this study, we tested the func-
tionality of this adaptation by subjecting mice to a metabolic
challenge of insulin resistance and hypertriglyceridaemia.
Cardiac glucose uptake was significantly increased by 1.5-
fold in Lxrα-Tg mice on an LFD compared with WT mice.
HFD caused a 1.4-fold increase in glucose uptake inWTmice,
but this was more markedly enhanced in Lxrα-Tg hearts
(Fig. 3a, b). LV protein levels of the insulin-dependent glucose
transporter 4 (GLUT4) were assessed by western blot
(Fig. 3c). GLUT4 was significantly upregulated by 1.6-fold
in Lxrα-Tg mice on an LFD. However, an HFD significantly
suppressed GLUT4 expression in WT mice, but this was re-
stored by LXRα overexpression.
In response to an HFD, phosphorylated 5′ adenosine
monophosphate-activated protein kinase (AMPK) was signifi-
cantly increased by 1.7-fold in Lxrα-Tg mice compared with
WT (Fig. 3d). Downstream Akt substrate of 160 kDa (AS160)
phosphorylation levels were also elevated in diabetic Lxrα-Tg
hearts, but not in WT-HFD hearts (Fig. 3e). Assessment of up-
stream kinases of AMPK revealed that liver kinase B1 (LKB1)
expression was induced in Lxrα-Tg mice both at baseline and
on an HFD, but not in WT mice (Fig. 3f), whereas Ca2+/
calmodulin-dependent protein kinase kinase-beta (CAMKKβ)
expression was increased by twofold in Lxrα-Tg-HFD hearts
compared with WT-HFD hearts (Fig. 3g), implicating a role in
Ca2+- or contraction-stimulated glucose uptake.
Overall, these data indicate that increased basal cardiac
glucose uptake in Lxrα-Tg mice is associated with induction
of the insulin-dependent GLUT4 transporter, and AMPK
phosphorylation may contribute to the enhanced glucose
uptake levels following an HFD. Hearts overexpressing car-
diac LXRα respond to HFD intervention by upregulating
LKB1 and CAMMKβ, which converge to activate AMPK
and promote GLUT4 translocation and upregulation via
phospho-AS160.
In separate experiments, a model of type 1 diabetes was
implemented (ESM Table 1, ESM Fig. 2). To further examine
the effects of insulin signalling on LXRα-mediated myocar-
dial glucose uptake, mice were rendered insulin-deficient via
STZ treatment. STZ caused a reduction of fasting insulin
levels by approximately 50% (ESM Table 1). As a conse-
quence, myocardial glucose uptake levels were severely
depressed in both WT and Lxrα-Tg mice treated with STZ
(ESM Fig. 2), which was associated with a decline in cardiac
function (ESM Table 1). In Lxrα-Tg hearts subjected to STZ,
the inability to upregulate phosphorylated AMPK levels was
Fig. 2 Cardiac-specific LXRα overexpression prevents obesity-induced
cardiac hypertrophy. WT (white bars), Lxrα-Tg (black bars). (a) LV to
tibia length ratios inWTand Lxrα-Tg mice fed an HFD for 16 weeks; n=
11–12/group. (b–g) Measurement of mRNA levels to assess hypertrophic
gene expression. Values are normalised to the invariant transcript, 36b4,
and are expressed as fold change; n=8–10/group. Data are means±SEM;
*p<0.05, **p<0.01, ***p<0.001 vs respective LFD control, †p<0.05,
††p<0.01, †††p<0.001 vs WT
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associated with significant reductions in GLUT4 expression
(ESM Fig. 2c, d). Taken together, cardiac LXRα overexpres-
sion augments cardiac glucose uptake despite systemic insulin
resistance. Nevertheless, the presence of insulin may be
necessary for an LXRα-mediated increase in glucose levels.
Cardiac LXRα overexpression induces transcriptional
changes in lipid metabolism Genes promoting cellular and
mitochondrial FA uptake such as fatty acid translocase (Cd36;
Fig. 4a) and carnitine parmitoyltransferase I (Cpt1a and
Cpt1b; Fig. 4c, d) were significantly downregulated in Lxrα-
Tg hearts in response to an HFD, suggesting a deviated shift
from FA oxidation pathways. Cardiac LXRα negatively reg-
ulates CD36 expression and positively regulates acetyl-CoA
carboxylase 2 (ACC2) expression (via an unknown mecha-
nism; Fig. 4b). On the other hand, cardiac LXRα also pro-
motes AMPK signalling (Fig. 3d), which potentially could
promote FA oxidation via translocation of CD36 and ACC2
phosphorylation. HFD did not cause substantial changes in
cardiac triacylglycerols, although these levels tended to be
lower in Lxrα-Tg mice (ESM Fig. 3). No detectable differ-
ences in the constitutive glucose transporter 1 (Glut1; also
known as Slc2a1) and hexokinase II (Hk2) mRNA levels were
observed between Lxrα-Tg and WT mice (Fig. 4e, f).
Natriuretic peptides are potential direct targets of LXRα
activationNatriuretic peptides, ANP and BNP, are induced in
response to cardiac stress or injury and are antihypertrophic in
their effects on the heart [19]. However, their concentrations
are decreased in obesity and type 2 diabetes despite the pres-
ence of cardiac hypertrophy and dysfunction [20]. LXRs may
play a regulatory role in natriuretic peptide expression since
Anp and BnpmRNA levels are significantly increased by 2.8-
fold and 3.0-fold, respectively, in mice with cardiac-specific
LXRα overexpression (described previously, [17]), and
Fig. 3 Cardiac LXRα
overexpression enhances
myocardial glucose uptake in
response to an HFD. (a, b) Mice
on either an LFD or HFD
underwent [18F]FDG and
microPET imaging to record
myocardial glucose uptake after
16 weeks on respective diets. (a)
[18F]FDG uptake was determined
as standard uptake value; n=5–6/
group. (b) Representative PET
images in coronal and axial
planes. (c–g) WT (white bars),
Lxrα-Tg (black bars).
Quantification of (c) GLUT4, (d)
AMPKα phosphorylation, (e)
AS160 phosphorylation, (f)
LKB1 and (g) CAMKKβ protein
levels in LV tissue normalised to
GAPDH; n=8/group, except
GLUT4 n=5–6/group. Data are
means±SEM; *p<0.05,
**p<0.01, ***p<0.001 vs
respective LFD control, †p<0.05,
††p<0.01, †††p<0.001 vs WT
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remain upregulated in the presence of HFD-induced obesity
(Fig. 2f, g).
To further evaluate the role of LXRα on myocardial natri-
uretic peptide transcription, in silico analysis of the ANP/BNP
region was performed using algorithms specific for the iden-
tification of LXR binding sites, or LXREs. In the mouse,
several potential LXREs were identified within ± 50 kb of
the Anp transcriptional start site (TSS). To determine whether
the LXR/RXR heterodimer is recruited to the ANP/BNP re-
gion, ChIP analysis was performed in murine heart tissue with
antibodies specific for LXRα. An LXRα antibody was suffi-
cient to pull down LXRE-containing DNA fragments of two
potential LXREs, LXRE 6 and LXRE 14 (Fig. 5a–e). Agarose
gel electrophoresis indicated that recruitment of LXRα to the
ANP/BNP region occurred in both WT and Lxrα-Tg mice.
This gel-based assay was used for quantitative assessment of
LXRE fragments by determining abundance of precipitated
genomic sequences by real-time PCR. IgG antibodies served
as a negative control, confirming lack of an interaction with
the LXRE under investigation.
To assess whether LXRE 14 is conserved, putative binding
sites for LXRE 14 in mouse, human and rat were identified
using the JASPAR database (http://jaspar.genereg.net;
Fig. 5a). A region of ± 50 kb from the TSS of the mouse
Anp gene was used together with syntenic regions in the
human and rat. These sequences were then scanned against
all available position frequency matrices using a relative
profile score threshold of 80%. Results from this analysis
revealed an occurrence of the LXRE 14 binding site in the
intronic region of Clcn6, approximately 30 kb downstream of
the TSS of mouse Anp (score, 89%). Comparison with
orthologous regions in the human and rat identified this site
as being highly conserved in human (score, 81%). Relaxing
the cut-off of the relative profile score to 70% identified
Fig. 4 Metabolic gene profile of LXRα transgenic hearts subjected to an
HFD. (a–f) WT (white bars), Lxrα-Tg (black bars). mRNA levels were
determined in LV samples following 16 weeks of either LFD or HFD for
genes involved in (a) fatty acid uptake, (b–d) mitochondrial import and
oxidation and (e, f) glucose uptake and metabolism. mRNA levels are
normalised to 36b4, and expressed as fold change; n=8–10/group. Data
are means±SEM; †p<0.05, ††p<0.01, †††p<0.001 vs WT Fig. 5 Regulation of natriuretic peptide transcription by LXRα. (a)
LXRE 14 binding site sequences for mouse, human and rat were identi-
fied using the JASPAR database. A region of ±50 kb from the TSS of the
Anp gene in mice was used together with syntenic regions in humans and
rats. Results from this analysis revealed a highly conserved LXRE 14
binding site in the intronic region of Clcn6 in both mouse and human
with a lower degree of conservation in the rat. (b–e) Chromatin immuno-
precipitation assays were performed in heart samples fromWTand Lxrα-
Tgmice to analyse the ANP/BNP region using antibodies directed against
LXRα. Analysis of immunoprecipitated chromatin fragments are from
two murine preparations per genotype, each preparation representing two
pooled hearts, normalised (norm.) to 36B4. (c, e) Ab:LXRα (black bars),
Ab:IgG (grey bars). The results are representative of the real-time PCR
fragments and are analysed from gel electrophoresis. Nonspecific IgG
antibodies served as a negative control. Ab, antibody; mu, murine
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LXRE 14 as being less stringently conserved in rat (score,
74%). Using ChIP assay, we further validated binding of
LXRα to this site in isolated rat cardiomyocytes (ESM Fig.
4a, b). LXRE 6 featured as a two-way binding site that was
highly conserved in mice (score, 90% and 80%) and rats
(score, 87% and 75%), but not in humans (ESM Fig. 4c).
In conclusion, LXRα may serve as an enhancer that binds
specifically to the ANP/BNP region to regulate natriuretic
peptide expression and mediate its antihypertrophic effects
in the heart. Since the Anp and Bnp genes do not overlap
genomically, but rather lie relatively close to each other, it is
likely that functional LXREs located within this locus may
influence the transcription of either gene or both.
Discussion
LXRs have been implicated as potential drug targets for the
treatment of diabetes and metabolic disorders given their role
in improving glucose tolerance and insulin resistance [5, 7, 8,
21]. In the present study, we investigated whether cardiac
LXRα protects the heart against diabetic cardiomyopathy.
We found that cardiac-specific LXRα overexpression in mu-
rine hearts prevented the development of obesity-induced LV
hypertrophy in the absence of overt cardiac dysfunction.
Despite hyperinsulinaemia and peripheral insulin resistance,
myocardial glucose uptakewas remarkably enhanced in Lxrα-
Tg mice on an HFD coincident with increased AMPK
activation and restoration of GLUT4.
Diabetic cardiomyopathy has become increasingly
recognised as a distinct clinical entity that is characterised by
the presence of cardiovascular damage in diabetic patients [3].
Although the existence of several risk factors associated with
diabetes, such as hypertension and coronary artery disease,
may amplify the effect of diabetes on the heart, diabetes nev-
ertheless incurs adverse changes to the myocardium, includ-
ing LV hypertrophy and fibrosis, in the absence of these con-
founding factors [22]. Mice with cardiac-specific LXRα over-
expression are protected from LV hypertrophy and dysfunc-
tion following hypertrophic perturbations such as chronic
pressure overload and angiotensin II stimulation [17]. Here,
we extend upon these observations demonstrating that the
hypertrophic response is further abrogated following a meta-
bolic challenge of chronic hypertriglyceridaemia and
hyperinsulinaemia. HFD intervention induced LV hypertro-
phy and molecular determinants of hypertrophic stress in
WT mice in the absence of fibrosis (data not shown) and
cardiac dysfunction, suggesting that hypertrophic remodelling
is a very early structural manifestation of cardiomyopathic
onset and progression. However, with longer duration of
HFD, we speculate that obesity-induced cardiac hypertrophy
may predispose mice to cardiac dysfunction, as LV hypertro-
phy is one of the main precursors of heart failure. Recently, the
LXR agonist GW3965 was reported to attenuate fibrosis and
apoptosis and improve cardiac function in diabetic db/dbmice
[16]. However, it is important to note that GW3965 also
lowered body weight as well as hyperglycaemia and hyper-
cholesterolaemia in these mice whilst improving glucose tol-
erance and insulin sensitivity [16], suggesting that the benefi-
cial effects of LXR agonism in the heart are likely to be a
result of less stress emanating from these systemic metabolic
disturbances. In our study, these systemic variables were com-
parable between WT and Lxrα-Tg groups, allowing strictly
for heart-specific evaluation of LXR activation.
To date, the metabolic effects of LXR in the diabetic heart
have not been described. Metabolic derangements caused by
HFD involve increased delivery of FA to the heart, which
steers substrate preference towards exclusively FA; this adap-
tation, coupled with insulin resistance, limits the dependence
on glucose. The heart is thus an inadvertent target of diabetes
[23]. In this study, we tested the functionality of the cardiac
LXRα transgene on myocardial glucose uptake capacity by
rendering mice either insulin resistant or deficient. In response
to HFD-induced insulin resistance, Lxrα-Tg mice neverthe-
less displayed increased myocardial glucose uptake, mediated
in part by restoration of insulin-dependent GLUT4 through
increased AMPK phosphorylation. By contrast, diabetes in-
voked by STZ-induced insulin deficiency led to impaired glu-
cose uptake and cardiac dysfunction, indicating that cardiac
LXRα overexpression may not be adequate to improve glu-
cose uptake capacity in the setting of type 1 diabetes.
Interestingly, the HFD tended to mildly increase cardiac
glucose uptake, which is consistent with a previous report
showing that HFD-induced hyperinsulinaemia augmented
glucose uptake in mice in the absence of cardiac dysfunction,
and moreover, this increase in glucose flux was critical for
preserving mitochondrial function [24]. Preceding the pre-
dominant utilisation of lipids that is a hallmark of diabetic
cardiomyopathy, the early phase of metabolic remodelling
may indeed be characterised by a heightened sensitivity to
insulin that promotes glucose uptake and usage. It remains
to be determined when the myocardium gradually develops
insulin resistance in the face of systemic insulin resistance.
Thus far, data from clinical studies are conflicting as myocar-
dial glucose supply is reported to be either unchanged [25] or
reduced [26] in diabetic patients.
Maintaining myocardial sensitivity to glucose, or reducing
FA uptake may nevertheless be key in preventing the progres-
sion of diabetes-associated pathogenesis. ImpairedGlut4 tran-
scription is linked to states of insulin resistance [27]. In light of
this, increasing GLUT4 levels may be cardioprotective. In this
study, phosphorylation and activation of AMPK by upstream
kinases, LKB1 and CAMKKβ, promoted GLUT4 upregula-
tion and translocation via AS160 phosphorylation in Lxrα-Tg
hearts subjected to an HFD, but not in WT. Other studies
support direct effects of LXR agonism on Glut4 transcription
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in adipose tissue and skeletal muscle, which enhance periph-
eral glucose clearance in rodent models of diabetes [5, 7, 9].
Moreover, expression of the FA uptake transporter gene,
Cd36, is reciprocally downregulated in Lxrα-Tg hearts, which
may confer antihypertrophic effects since Cd36 knockout
mice are resistant to HFD-induced cardiac hypertrophy [28].
By contrast, increased CD36 expression in middle-aged mice
contributes to cardiac hypertrophy, dysfunction and myocar-
dial lipid accumulation [29].
Besides modulation of myocardial substrate metabolism,
targeting of natriuretic peptides beyond their established ef-
fects on pressure–volume homeostasis may be important in
preventing diabetic cardiomyopathy. A cardiometabolic link
has been postulated for natriuretic peptides [20], and BNP is
implicated in improved glucose utilisation through increased
capillary permeability [30]. Natriuretic peptides are also
known to antagonise cardiac hypertrophy independently of
blood pressure [31, 32], and in humans, certain ANP- and
BNP-receptor polymorphisms have been associated with LV
mass in essential hypertension [33]. Both Anp and Bnp are
significantly upregulated with cardiac LXRα overexpression
and their induction is unaffected by HFD-induced obesity. By
contrast, natriuretic peptides are deficient in obesity and dia-
betes, as obese and insulin-resistant individuals display re-
duced circulating ANP and BNP levels [34, 35], despite the
fact that these metabolic disorders increase the risk of devel-
oping cardiovascular disease and heart failure. HFD interven-
tion did not affect natriuretic peptide expression; however, this
may be model-dependant as other preclinical studies show
that ANP and BNP are downregulated in diabetic db/db mice
[36, 37]. It is currently unknown why natriuretic peptides are
dysregulated in this setting. However, treatment with BNP has
been shown to prevent cardiac dysfunction in db/db mice by
inhibiting cardiac hypertrophy, fibrosis and apoptosis [37], as
well as the acute hypertrophic response in the diabetic rat heart
[38]. LXRα may therefore prevent obesity-induced cardiac
hypertrophy via increased local natriuretic peptide signalling.
Unravelling the mechanisms by which LXRα modulates Anp
and Bnp transcription may indeed be complex: activation of
the hexosamine biosynthetic pathway through increased glu-
cose flux leads to downstreamO-linked glycosylation of tran-
scriptional activators of ANP and BNP [17]. Additionally, this
study identified putative LXREs in regulatory regions of the
ANP/BNP promoter and ChIP analysis confirmed recruitment
of LXRα to this region, implicating natriuretic peptides as
direct, heart-specific gene targets of LXRα.
Since the structural consequences of diabetes-imposed
metabolic stress on the heart are slow and progressive effects,
and the clinical manifestation of symptoms is gradual, an un-
derstanding of the initial derangements is essential for early
intervention. Herein, we capture a very early stage in the path-
ogenesis of diabetic cardiomyopathy and show that cardiac
hypertrophy and glucose response to metabolic stress are
preliminary developments. Promoting glucose uptake as well
as natriuretic peptide signalling in the heart may be important
initiatives in counteracting the progression of diabetes-
induced myocardial disease. Interestingly, the recently pub-
lished PARADIGM study [39] demonstrated the beneficial
effects of LCZ696 in patients with heart failure. LCZ696 in-
creases circulating BNP levels and it would be of particular
interest to test this novel drug in patients with diabetes. Alto-
gether, our results support the notion that targeting LXRαmay
be advantageous for intervening in aberrant metabolic signal-
ling, which is a hallmark of cardiovascular disease.
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